These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 26846728)

  • 1. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
    Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.
    Molino S; Martin MT
    Ann Pharmacother; 2017 Sep; 51(9):811-816. PubMed ID: 28480743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
    McConachie SM; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2016; 9(2):287-302. PubMed ID: 26651915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.
    Chayama K; Hayes CN
    Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients.
    Cholongitas E; Pipili C; Papatheodoridis G
    World J Gastroenterol; 2015 Aug; 21(32):9526-33. PubMed ID: 26327760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C therapy: Looking toward interferon-sparing regimens.
    Au TH; Destache CJ; Vivekanandan R
    J Am Pharm Assoc (2003); 2015; 55(2):e72-84; quiz e85-6. PubMed ID: 25658389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
    Perelló C; Carrión JA; Ruiz-Antorán B; Crespo J; Turnes J; Llaneras J; Lens S; Delgado M; García-Samaniego J; García-Paredes F; Fernández I; Morillas RM; Rincón D; Porres JC; Prieto M; Lázaro Ríos M; Fernández-Rodríguez C; Hermo JA; Rodríguez M; Herrero JI; Ruiz P; Fernández JR; Macías M; Pascasio JM; Moreno JM; Serra MÁ; Arenas J; Real Y; Jorquera F; Calleja JL;
    J Viral Hepat; 2017 Mar; 24(3):226-237. PubMed ID: 27976491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C: a systematic review.
    Kohli A; Shaffer A; Sherman A; Kottilil S
    JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
    Su F; Green PK; Berry K; Ioannou GN
    Hepatology; 2017 Feb; 65(2):426-438. PubMed ID: 27775854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
    Su F; Beste LA; Green PK; Berry K; Ioannou GN
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):686-693. PubMed ID: 28195877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hepatitis C: Results in real life.
    Hézode C
    Liver Int; 2018 Feb; 38 Suppl 1():21-27. PubMed ID: 29427481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Pricing Evolution in Hepatitis C.
    Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
    PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.
    Sarrazin C; Buggisch P; Mauss S; Müller T; Zimmermann T; Klinker H; Pathil-Warth A; Schlag M; Nalpas C; Wegner S; Lonjon-Domanec I; Simon KG
    Z Gastroenterol; 2019 May; 57(5):584-592. PubMed ID: 31083746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.
    Fox DS; McGinnis JJ; Tonnu-Mihara IQ; McCombs JS
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1136-1142. PubMed ID: 27869323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
    Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Direct Acting Antiviral Agents for the Treatment of Hepatitis C: 2016 and Beyond.
    Umar M; Akhter TS
    J Coll Physicians Surg Pak; 2016 Oct; 26(10):843-850. PubMed ID: 27806815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection.
    Toussaint-Miller KA; Andres J
    Ann Pharmacother; 2015 Sep; 49(9):1015-30. PubMed ID: 26139639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.